CL2021000207A1 - Nuevas proteínas de fusión específicas para cd137 y pd-l1 - Google Patents

Nuevas proteínas de fusión específicas para cd137 y pd-l1

Info

Publication number
CL2021000207A1
CL2021000207A1 CL2021000207A CL2021000207A CL2021000207A1 CL 2021000207 A1 CL2021000207 A1 CL 2021000207A1 CL 2021000207 A CL2021000207 A CL 2021000207A CL 2021000207 A CL2021000207 A CL 2021000207A CL 2021000207 A1 CL2021000207 A1 CL 2021000207A1
Authority
CL
Chile
Prior art keywords
fusion proteins
compositions
nucleic acid
acid molecules
methods
Prior art date
Application number
CL2021000207A
Other languages
English (en)
Inventor
Marlon Hinner
Christine Rothe
Shane Olwill
Marina Pavlidou
Lucia Pattarini
Alix Scholer-Dahirel
Aiba Rachida Bel
Janet Peper
Original Assignee
Servier Lab
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Pieris Pharmaceuticals Gmbh filed Critical Servier Lab
Publication of CL2021000207A1 publication Critical patent/CL2021000207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La descripción provee proteínas de fusión específicas tanto para CD137 como para PD-L1, las cuales pueden ser utilizadas para coestimular activación de linfocitos de una manera dependiente de la diana-PD-L11. Dichas proteínas de fusión pueden ser utilizadas en muchas aplicaciones farmacéuticas, por ejemplo como agentes anticáncer y/o inmunomoduladores para el tratamiento o prevención de enfermedades humanas tales como una variedad de tumores. La presente descripción también se refiere a métodos de preparar las proteínas de fusión descriptas en la presente así como composiciones que comprenden dichas proteínas de fusión. La presente descripción también se refiere a moléculas de ácido nucleico que codifican dichas proteínas de fusión y a métodos para la generación de dichas proteínas de fusión y moléculas de ácido nucleico. Además, la solicitud describe usos diagnósticos y/o terapéuticos de dichas proteínas de fusión así como composiciones que comprenden una o más de dichas proteínas de fusión.
CL2021000207A 2018-07-31 2021-01-26 Nuevas proteínas de fusión específicas para cd137 y pd-l1 CL2021000207A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18204548 2018-11-06

Publications (1)

Publication Number Publication Date
CL2021000207A1 true CL2021000207A1 (es) 2021-08-13

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000207A CL2021000207A1 (es) 2018-07-31 2021-01-26 Nuevas proteínas de fusión específicas para cd137 y pd-l1

Country Status (28)

Country Link
US (1) US20210363257A1 (es)
EP (2) EP3830120B9 (es)
JP (1) JP7482488B2 (es)
KR (1) KR20210040103A (es)
CN (1) CN112789292A (es)
AU (1) AU2019315703A1 (es)
BR (1) BR112020025263A2 (es)
CA (1) CA3100119A1 (es)
CL (1) CL2021000207A1 (es)
CY (1) CY1126148T1 (es)
DK (1) DK3830120T5 (es)
ES (1) ES2948717T3 (es)
FI (1) FI3830120T3 (es)
HR (1) HRP20230590T2 (es)
HU (1) HUE062320T2 (es)
IL (1) IL279541A (es)
LT (1) LT3830120T (es)
MD (1) MD3830120T3 (es)
MX (1) MX2021000401A (es)
MY (1) MY200710A (es)
PH (1) PH12021550001A1 (es)
PL (1) PL3830120T3 (es)
RS (1) RS64343B9 (es)
SG (1) SG11202100989UA (es)
SI (1) SI3830120T1 (es)
TW (1) TWI837156B (es)
WO (1) WO2020025659A1 (es)
ZA (1) ZA202100125B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513693A (ja) * 2018-11-29 2022-02-09 ハーバー・バイオメド・セラピューティクス・リミテッド 抗ｐｄ－ｌ１抗体製剤
WO2020201038A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
JP7634001B2 (ja) 2019-10-11 2025-02-20 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途
CA3177098A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
CN116710556A (zh) * 2021-01-08 2023-09-05 北京韩美药品有限公司 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
PE20251544A1 (es) * 2022-09-21 2025-06-05 Seagen Inc Nueva proteina de fusion especifica para cd137 y cd228
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CN1170543C (zh) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CN107820500B (zh) * 2015-05-04 2022-03-01 皮里斯制药有限公司 Cd137特异性的蛋白
EP4378962A3 (en) * 2015-05-04 2024-07-31 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
AU2016262845B2 (en) * 2015-05-18 2020-07-23 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
CN108779176A (zh) * 2016-01-11 2018-11-09 印希比股份有限公司 多价和多特异性41bb结合融合蛋白
CN107151269B (zh) * 2016-03-04 2021-07-27 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途
PE20190510A1 (es) * 2016-06-13 2019-04-10 I Mab Anticuerpos anti-pd-l1 y usos de los mismos
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
KR102678252B1 (ko) * 2017-09-01 2024-06-26 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 재조합 이중특이적 항체
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Also Published As

Publication number Publication date
MY200710A (en) 2024-01-12
PL3830120T3 (pl) 2023-10-09
HRP20230590T1 (hr) 2023-09-15
ES2948717T3 (es) 2023-09-18
KR20210040103A (ko) 2021-04-12
EP4249064A3 (en) 2023-12-06
CA3100119A1 (en) 2020-02-06
PH12021550001A1 (en) 2021-09-27
RS64343B1 (sr) 2023-08-31
SG11202100989UA (en) 2021-02-25
BR112020025263A2 (pt) 2021-03-09
EP3830120B1 (en) 2023-05-24
MX2021000401A (es) 2021-03-25
ZA202100125B (en) 2023-06-28
JP2021533203A (ja) 2021-12-02
TWI837156B (zh) 2024-04-01
DK3830120T3 (da) 2023-06-26
CN112789292A (zh) 2021-05-11
LT3830120T (lt) 2023-07-10
FI3830120T3 (fi) 2023-06-13
AU2019315703A1 (en) 2020-12-10
EP3830120B9 (en) 2023-08-30
CY1126148T1 (el) 2023-11-15
EP4249064A2 (en) 2023-09-27
SI3830120T1 (sl) 2023-10-30
EP3830120A1 (en) 2021-06-09
IL279541A (en) 2021-01-31
WO2020025659A1 (en) 2020-02-06
JP7482488B2 (ja) 2024-05-14
HUE062320T2 (hu) 2023-10-28
MD3830120T2 (ro) 2023-08-31
DK3830120T5 (da) 2024-08-19
RS64343B9 (sr) 2023-11-30
HRP20230590T2 (hr) 2024-02-16
MD3830120T3 (ro) 2023-11-30
US20210363257A1 (en) 2021-11-25
TW202019967A (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX390894B (es) Polipéptido de fusión anti-cáncer.
EP4378962A3 (en) Anti-cancer fusion polypeptide
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
ECSP17061751A (es) Nuevas proteínas específicas para pioverdina y pioquelina
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
BR112018016281A2 (pt) molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
HK1254450A1 (zh) 对lag-3和pd-1特异性的新型融合多肽
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
ECSP15025845A (es) Anticuerpos anti-ceacam5 y usos de éstos
BR112014019459A8 (pt) Proteínas de ligação à cdim e usos das mesmas
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX2025006169A (es) Inmunoglobulinas de enlace a mmp13
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
BR112017024714A2 (pt) métodos para preparação do fator de von willebrand modificado
AR115878A1 (es) Proteínas de fusión específicas para cd137 y pd-l1
MX2023006830A (es) Inmunocitoquina para activar el receptor il-10ra humano y su uso.